Polymyalgia rheumatica (PMR) is an inflammatory disorder of unknown aetiology that can be extremely disabling when active. Glucocorticoids are currently the therapy of choice for patients with PMR, ...

March 12, 2012 — Diagnosis of polymyalgia rheumatica (PMR) has started to move from the realm of clinical intuition toward a more objective approach, after the release of provisional classification ...

Polymyalgia rheumatica (PMR) can be difficult to diagnose because of its protean manifestations that include aches and pains, fever, liver test abnormalities, peripheral edema, overlap of symptoms and ...

The exact cause of polymyalgia rheumatica (PMR) is unknown. Studies of patients with PMR and giant-cell arteritis indicate that PMR could be a vasculitis limited to the subclavian or axillary arteries ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved sarilumab for the treatment of polymyalgia rheumatica in adults who have experienced an ...

Please provide your email address to receive an email when new articles are posted on . Recent data demonstrated, however, the utility of ultrasonography to detect biceps tenosynovitis and subdeltoid ...

Polymyalgia rheumatica causes pain and swelling in joints and muscles, mainly in the hips, neck, and shoulders. Pain and swelling may be worse in the morning. This condition can occur quickly and ...

(RTTNews) - Novartis (NVS,NOVN.SW) announced that its interleukin-17A inhibitor Cosentyx (secukinumab) met the primary and all secondary endpoints in the Phase III REPLENISH trial. The study evaluated ...

For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is ...

Tofacitinib (Xeljanz) appeared highly effective against polymyalgia rheumatica (PMR) in a small single-arm trial, researchers said, suggesting another potential alternative to long-term ...

The Global Healthy Living Foundation (GHLF) is excited to present innovative and transformative research at the American College of Rheumatology (ACR) Convergence 2024 in Washington DC. This marks ...